Bristol-Myers Squibb

3Q Revenues: $4.9 billion (+21%)

3Q Earnings: $1.2 billion (+66%)

YTD Revenues: $12.9 billion (+16%)

YTD Earnings: $3.6 billion (+98%)

Comments: U.S. revenues increased 36% to $2.8 billion in the quarter and international revenues increased 5%.  Opdivo sales were $920 million in the quarter, up from $305 million 3Q15.Eliquis sales were up 90% to $84 million; Yervoy sales were up 19% to $285 million; Orencia sales grew 18% to $572 million; and Sprycel sales were up 15% to $472 million.The company’s virology product sales were down in the quarter. Baraclude sales were down 4% to $306 million; Hepatitis C Franchise sales were down 6% to $379 million; Reyataz sales were down 12% to $238 million; and Sustiva sales were 275 million, down 17%. Erbitux and Abilify are now trademarks of ImClone LLC and Otsuka Pharmaceutical Co., Ltd., respectively. Research and development expenses increased 1% to $1.1 billion in the quarter.